Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $46.00 at HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL) had its target price boosted by HC Wainwright from $44.00 to $46.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Several other research firms also recently issued reports on COLL. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.25.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded up $1.64 on Friday, reaching $42.30. 864,974 shares of the company traded hands, compared to its average volume of 414,440. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $43.06. The company’s 50 day moving average is $35.70 and its 200-day moving average is $32.76. The stock has a market capitalization of $1.33 billion, a PE ratio of 26.27 and a beta of 0.61. The company has a debt-to-equity ratio of 2.94, a current ratio of 1.54 and a quick ratio of 1.10.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business had revenue of $135.55 million for the quarter. As a group, analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 17,478 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $38.42, for a total transaction of $671,504.76. Following the completion of the sale, the executive vice president directly owned 70,264 shares in the company, valued at approximately $2,699,542.88. This trade represents a 19.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Colleen Tupper sold 30,000 shares of Collegium Pharmaceutical stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the sale, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. The trade was a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 74,133 shares of company stock worth $2,899,504 in the last quarter. 2.51% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Federated Hermes Inc. lifted its holdings in shares of Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the last quarter. CWM LLC raised its position in Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,153 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in Collegium Pharmaceutical by 137.7% in the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 993 shares during the last quarter. Wealthquest Corp bought a new stake in Collegium Pharmaceutical in the first quarter worth approximately $62,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.